Intense lipid-lowering 'benefits elderly' after ACS
Secondary analysis of IMPROVE-IT trial could influence guidelines, authors say
25th July 2019
Adding ezetimibe to intensive statin therapy following acute coronary syndrome provides greater benefits to elderly patients than those in lower age groups, a US study has found.
In a secondary analysis of the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study, researchers compared the effects of simvastatin-ezetimibe combination therapy versus simvastatin alone by age group in more than 18,000 participants (mean age 64).
The original IMPROVE-IT findings, published in 2015, demonstrated the
